A review of the adverse effects and safety of noradrenergic antidepressants

Journal of Psychopharmacology

Volumn 27, Issue 8, 2013, Pages 732-739

  Whiskey, Eromona ^a   Taylor, David ^a,b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

adverse drug reaction; Antidepressant agent; noradrenaline

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DOMAZOLINE; DULOXETINE; FLUOXETINE; IMIPRAMINE; LOFEPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAMSULOSIN; TERAZOSIN; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANORGASMIA; ANXIETY DISORDER; AUTONOMIC DYSFUNCTION; CARDIOMETABOLIC RISK; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMA; CONSTIPATION; CONVULSION; DEPRESSION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; EJACULATION DISORDER; ELECTROCARDIOGRAM; FATIGUE; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HEART MUSCLE CONTRACTILITY; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPONATREMIA; INSOMNIA; LIBIDO DISORDER; LIVER TOXICITY; METABOLIC DISORDER; MYDRIASIS; NAUSEA; NEUROPATHIC PAIN; NOCTURNAL ENURESIS; NORADRENERGIC SYSTEM; ORTHOSTATIC HYPOTENSION; PR INTERVAL; PRIORITY JOURNAL; PULSE RATE; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RESTLESSNESS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEIZURE; SEROTONIN SYNDROME; SEXUAL AROUSAL DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; STRESS INCONTINENCE; SUICIDAL IDEATION; SWEAT GLAND DISEASE; SWEATING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREMOR; URINARY FREQUENCY; URINARY HESITANCY; URINE INCONTINENCE; URINE RETENTION; UROGENITAL TRACT DISEASE; VOMITING; XEROSTOMIA;

ADVERSE DRUG REACTION; ANTIDEPRESSANT AGENT; NORADRENALINE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MORPHOLINES; NOREPINEPHRINE; SEROTONIN UPTAKE INHIBITORS;

EID: 84880501002     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113492027     Document Type: Review

References (111)

1. Abdelrahman N, Kleinman Y, Rund D, et al. Hyponatremia associated with the initiation of reboxetine therapy. Eur J Clin Pharmacol. 2003 ; 59: 177
2. Agelink MW, Ullrich H, Baumann B, et al. Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: Preliminary data. Psychopharmacology (Berl). 2002 ; 163: 151-156
3. Akkaya C, Sivrioglu EY, Akgoz S, et al. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study. Hum Psychopharmacol. 2006 ; 21: 337-345
4. Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009 ; 166: 591-598
5. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 ; 7: 249-264
6. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol. 2006 ; 20: 91-96
7. Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: A comparative study with desipramine, with methodological considerations. Hum Psychopharmacol. 1998 ; 13: S29 - S39
8. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008 ; 47: 209-218
9. Berger M, Riemann D. Symposium: Normal and abnormal REM sleep regulation: REM sleep in depression-an overview. J Sleep Res. 1993 ; 2: 211-223
10. Berzewski H, Van MM, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol. 1997 ; 7: S37 - S47
11. Bouman WP, Johnson H, Trescoli-Serrano C, et al. Recurrent hyponatremia associated with sertraline and lofepramine. Am J Psychiatry. 1997 ; 154: 580
12. Brown LC, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract. 2008 ; 79: 61-67
13. Buecking A, Vandeleur CL, Khazaal Y, et al. Mirtazapine in drug-induced excessive sweating. Eur J Clin Pharmacol. 2005 ; 61: 543-544
14. Burns MJ. The pharmacology and toxicology of reboxetine. Int J Med Toxicol. 2000 ; 3: 1-7
15. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet. 2009 ; 373: 746-758
16. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry. 2006 ; 67: S33 - S37
17. Clayton AH, Zajecka J, Ferguson JM, et al. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol. 2003 ; 18: 151-156
18. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: Population based cohort study. Brit Med J. 2011 ; 343: d4551
19. De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996 ; 57: S19 - S25
20. De Groot M., Anderson R, Freedland KE, et al. Association of depression and diabetes complications: A meta-analysis. Psychosom Med. 2001 ; 63: 619-630
21. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry. 2005 ; 66: 686-692
22. Demyttenaere K, Huygens R, Van BR. Tamsulosin as an effective treatment for reboxetine-associated urinary hesitancy. Int Clin Psychopharmacol. 2001 ; 16: 353-355
23. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004 ; 14: 457-470
24. Deuschle M. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Curr Opin Psychiatry. 2013 ; 26: 60-65
25. Eli Lilly and Company Limited (2012) Summary of product characteristics. Cymbalta 30 mg hard gastro-resistant capsules, Cymbalta 60 mg hard gastro-resistant capsules. Available at: http://www.medicines.org.uk/ (accessed 4 June 2013). emc/medicine/15694/SPC/Cymbalta+30mg+hard+gastro- resistant+capsules%2c+Cymbalta+60mg+hard+gastro-resistant+capsules/ (accessed 4 June 2013).
26. Eli Lilly and Company Limited (2013) Summary of product characteristics. Strattera 10 mg, 18 mg, 25 mg, 40 mg, 60 mg or 80 mg hard capsules. Available at: http://www.medicines.org.uk/ (accessed 4 June 2013).
27. Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: Systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. Brit Med J. 2010 ; 341: c4737
28. Fava M, McGrath PJ, Sheu WP. Switching to reboxetine: An efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol. 2003 ; 23: 365-369
29. Feder R. Clonidine treatment of excessive sweating. J Clin Psychiatry. 1995 ; 56: 35
30. Ferini-Strambi L, Manconi M, Castronovo V, et al. Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia. J Psychopharmacol. 2004 ; 18: 417-422
31. Fleishaker JC, Francom SF, Herman BD, et al. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther. 2001 ; 70: 261-269
32. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008 ; 9: 453-466
33. Gelenberg AJ, McGahuey C, Laukes C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry. 2000 ; 61: 356-360
34. Ghaleiha A, Shahidi KM, Afzali S, et al. Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: A randomized controlled trial. Int J Psychiatry Clin Pract. 2012 ; 17: 44-47
35. Giuliano F, Rampin O. Central noradrenergic control of penile erection. Int J Impot Res. 2000 ; 12: S13 - S19
36. Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: Rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry. 2010 ; 196: 354-358
37. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. Brit Med J. 1995 ; 310: 221-224
38. Jacob J, Albert D, Heard K. Single-agent duloxetine ingestions. Hum Exp Toxicol. 2012 ; 32: 427-433
39. Jefferson JW. A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom Med. 1975 ; 37: 160-179
40. Kasper S, Wolf R. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. Eur Neuropsychopharmacol. 2002 ; 12: 119-122
41. Katona C, Bercoff E, Chiu E, et al. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: A double-blind randomised trial. J Affect Disord. 1999 ; 55: 203-213
42. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J. Clin Psychopharmacol. 2009 ; 29: 157-164
43. Kennedy SH, Dickens SE, Eisfeld BS, et al. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord. 1999 ; 56: 201-208
44. Khawaja IS, Feinstein RE. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. Heart Dis. 2003 ; 5: 153-160
45. Kuenzel HE, Murck H, Held K, et al. Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression. Pharmacopsychiatry. 2004 ; 37: 193-195
46. Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: A double-blind study in patients with major depressive disorder. J Clin Psychopharmacol. 2006 ; 26: 121-127
47. Mbaya P, Alam F, Ashim S, et al. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol. 2007 ; 22: 129-133
48. McIntyre RS, Panjwani ZD, Nguyen HT, et al. The hepatic safety profile of duloxetine: A review. Expert Opin Drug Metab Toxicol. 2008 ; 4: 281-285
49. McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: Synthesis and mechanisms. Expert Opin Drug Saf. 2006 ; 5: 157-168
50. Marcy TR, Britton ML. Antidepressant-induced sweating. Ann Pharmacother. 2005 ; 39: 748-752
51. Martinez C, Assimes TL, Mines D, et al. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: A nested case-control study. Brit Med J. 2010 ; 340: c249
52. Medicines and Healthcare Products Regulatory Agency (2011) MHRA UK Public Assessment Report: Reboxetine: A review of the benefits and risks. Available at: http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/ con129107.pdf (accessed 4 June 2013).
53. Medicines and Health Care Regulatory Authority (2006). Message from Professor G Duff, Chairman, Commission on Human Medicines - Strattera (atomoxetine) - conclusions of risk: benefit review. Available at: http://www.mhra.gov.uk/home/groups/comms-po/documents/websiteresources/ con2023220.pdf (accessed 4 June 2013).
54. Mehtonen OP, Sogaard J, Roponen P, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry. 2000 ; 61: 95-100
55. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry. 2003 ; 53: 112-120
56. Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001 ; 62: 10-21
57. Montgomery SA, Huusom AK, Bothmer J.. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004 ; 50: 57-64
58. Movig KL, Leufkens HG, Lenderink AW, et al. Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly. Eur J Clin Pharmacol. 2002 ; 58: 143-148
59. Munoz M, Bancroft J, Beard M. Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. 2. The erectile response to erotic stimuli in men with erectile dysfunction, in relation to age and in comparison with normal volunteers. Psychopharmacology (Berl). 1994 ; 115: 471-477
60. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998 ; 55: 580-592
61. Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol. 2002 ; 17: S37 - S41
62. Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006 ; 67: S3 - S8
63. Ozmenler NK, Karlidere T, Bozkurt A, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol. 2008 ; 23: 321-326
64. Papakostas GI, Nelson JC, Kasper S, et al. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2008 ; 18: 122-127
65. Parmar S, Behere PB. Hyponatraemia in patients receiving selective serontonin re-uptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs): A controlled study. Conference abstract, 62nd Annual Conference of Indian Psychiatric Society ; 2010 Jaipur, India ; 2010..
66. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: Tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl. 2000 ; 403: 17-25
67. Pfizer Limited (2012) Summary of product characteristics. Efexor XL. Available at: http://www.medicines.org.uk/emc/medicine/2210/SPC/Efexor+XL/
68. Pinder RM, Brogden RN, Speight TM, et al. Viloxazine: A review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977 ; 13: 401-421
69. Preskorn SH. Reboxetine: A norepinephrine selective reuptake pump inhibitor. J Psychiatr Pract. 2004 ; 10: 57-63
70. Quirk KC, Einarson TR. Sexual dysfunction and clomipramine. Can J Psychiatry. 1982 ; 27: 228-231
71. Ranieri P, Franzoni S, Trabucchi M. Reboxetine and hyponatremia. N Engl J Med. 2000 ; 342: 215-216
72. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry. 2003 ; 64: 1237-1244
73. Ravindran LN, Eisfeld BS, Kennedy SH. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function. J Clin Psychopharmacol. 2008 ; 28: 107-108
74. Richelson E. Tricyclic antidepressants and histamine H1 receptors. Mayo Clin Proc. 1979 ; 54: 669-674
75. Roos JC. Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine. Br J Clin Pharmacol. 1983 ; 15: S439 - S445
76. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database. J Clin Psychopharmacol. 1996 ; 16: S54 - S59
77. Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure: A meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006 ; 48: 1527-1537
78. Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatry. 2004 ; 161: 757
79. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry. 2000 ; 61: S31 - S38
80. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol. 2009 ; 29: 259-266
81. Simpson D, Plosker GL. Atomoxetine: A review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004 ; 64: 205-222
82. Singh T. Atomoxetine-induced hyponatremia. Aust N Z J Psychiatry. 2007 ; 41: 458
83. Southwick SM, Bremner JD, Rasmusson A, et al. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry. 1999 ; 46: 1192-1204
84. Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry. 1998 ; 59: S23 - S29
85. Stahl SM, Grady MM, Moret C, et al. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005 ; 10: 732-747
86. Stahl SM, Mendels J, Schwartz GE. Effects of reboxetine on anxiety, agitation, and insomnia: Results of a pooled evaluation of randomized clinical trials. J Clin Psychopharmacol. 2002 ; 22: 388-392
87. Strombom I, Wernicke JF, Seeger J, et al. Hepatic effects of duloxetine-III: Analysis of hepatic events using external data sources. Curr Drug Saf. 2008 ; 3: 154-162
88. Sumner CR, Schuh KJ, Sutton VK, et al. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol. 2006 ; 16: 699-711
89. Szabadi E. Doxazosin for reboxetine-induced urinary hesitancy. Br J Psychiatry. 1998 ; 173: 441-442
90. Szabadi E, Bradshaw CM, Boston PF, et al. The human pharmacology of reboxetine. Hum Psychopharmacol. 1998 ; 13: S3 - S12
91. Tanum L. Reboxetine: Tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl. 2000 ; 402: 37-40
92. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 ; 340: 249-258
93. Taylor D. Antidepressant drugs and cardiovascular pathology: A clinical overview of effectiveness and safety. Acta Psychiatr Scand. 2008 ; 118: 434-442
94. Taylor D, Scott JR. Volte-face on venlafaxine-reasons and reflections. J Psychopharmacol. 2006 ; 20: 597-601
95. Taylor D, Paton C, Kapur S Maudsley Prescribing Guidelines in Psychiatry. 2012 ) Maudsley Prescribing Guidelines in Psychiatry. 11th ed.Oxford, UK: Wiley-Blackwell. Oxford, UK: Wiley-Blackwell ; 2012:
96. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: Cardiovascular toxicity. Toxicol Rev. 2005 ; 24: 205-214
97. Thase ME. Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998 ; 59: 502-508
98. Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: A randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol. 2006 ; 26: 250-258
99. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005 ; 25: 132-140
100. Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med. 2006 ; 21: 30-38
101. Thor KB, Kirby M, Viktrup L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: Scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract. 2007 ; 61: 1349-1355
102. Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis. CMAJ. 1998 ; 159: 1245-1252
103. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol. 2000 ; 20: 28-34
104. Vey EL, Kovelman I. Adverse events, toxicity and post-mortem data on duloxetine: Case reports and literature survey. J Forensic Leg Med. 2010 ; 17: 175-185
105. Viktrup L, Pangallo BA, Detke MJ, et al. Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. Prim Care Companion J Clin Psychiatry. 2004 ; 6: 65-73
106. Vuppalanchi R, Hayashi PH, Chalasani N, et al. Duloxetine hepatotoxicity: A case-series from the drug-induced liver injury network. Aliment Pharmacol Ther. 2010 ; 32: 1174-1183
107. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin. 2007 ; 23: 1605-1614
108. Watanabe N, Omori IM, Nakagawa A, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: Systematic review and meta-analysis. CNS Drugs. 2010 ; 24: 35-53
109. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand. 2006 ; 114: 384-397
110. Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: Findings from 42 placebo-controlled studies. Drug Saf. 2007 ; 30: 437-455
111. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003 ; 26: 729-740